Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bavarian Nordic A/S is a Danish biotechnology company specializing in the research, development, manufacturing, and commercialization of innovative vaccines based on viral vector technologies. Headquartered in Hellerup, Denmark, with manufacturing facilities in Denmark and Switzerland, and R&D sites in Germany plus offices across North America and Europe, it leverages proprietary platforms like MVA-BN, a non-replicating Modified Vaccinia Ankara vector designed for safety and efficacy. The company markets approved vaccines including Jynneos/Imvanex/Imvamune for smallpox and mpox, Rabipur/RabAvert for rabies, Encepur for tick-borne encephalitis, Mvabea as part of an Ebola regimen, Vivotif for typhoid, Vaxchora for cholera, and the recently approved Vimkunya for chikungunya. Bavarian Nordic plays a critical role in global public health, supplying vaccines to government stockpiles, combating outbreaks like mpox and Ebola, and expanding into travel health and biodefense, while advancing a pipeline targeting equine encephalitis and other infectious diseases.
DKK 24.10
+DKK 0.74 (+3.17%)
Live · 10:05 PM · Twelve Data
28.90% operating margin is above average. ROIC at 11.23%.
Revenue grew 9.2%, steady but not accelerating.
Even for strong businesses, today's 2x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
1.6x earnings, 1.6x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
DKK 5.96B
▲ +9.2% YoY
Net Income (TTM)
DKK 1.17B
▲ +39.2% YoY
Op. Margin
25.83%
▲ +12.5pp YoY
ROIC
11.23%
▲ +2.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
DKK 1.31B
▲ +419.7% YoY
Op. Cash Flow (TTM)
DKK 2.10B
▲ +27.4% YoY
Net Debt
-DKK 3.20B
Net Cash Position
Cash & Equiv.
DKK 3.33B
3Y CAGR: +25.6%
Continue Research
At a P/E of 1.6 and a price-to-free-cash-flow of 1.6, Bavarian Nordic A/S (BAVA.XCSE) trades below a two-stage DCF intrinsic value of about DKK 816.17 per share, so at DKK 24.10 the stock looks undervalued (3,286.6% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bavarian Nordic A/S scores 86/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about DKK 816.17 per share for BAVA.XCSE, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around DKK 612.13. At today's DKK 24.10, that puts the stock about 3,286.6% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Bavarian Nordic A/S scores 86 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 25.8% operating margin and a 11.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BAVA.XCSE currently trades below its estimated intrinsic value and scores 86/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.